Revisiting bleomycin from pathophysiology to safe clinical use

Area of Science:

• Oncology
• Pulmonology
• Pharmacogenomics

Background:

• Bleomycin is a crucial chemotherapy agent for Hodgkin lymphoma (HL) and testicular germ-cell tumours (GCT).
• Bleomycin-induced lung injury (BILI) is a serious, potentially fatal side effect, diagnosed by exclusion.
• Current diagnostic methods for BILI lack specificity, necessitating improved risk assessment.

Purpose of the Study:

• To review current data on bleomycin's chemical biology, pharmacology, and clinical use.
• To explore the potential of pharmacogenomics in predicting and preventing BILI.
• To provide updated guidelines for the safe clinical application of bleomycin.

Main Methods:

• Comprehensive literature review of integrated chemical biology, molecular pharmacology, and clinical data.
• Analysis of existing studies on bleomycin toxicity and patient outcomes.
• Synthesis of findings to inform clinical practice and future research directions.

Main Results:

• Bleomycin's efficacy in HL and GCT is established, but BILI remains a significant concern with 1-3% mortality.
• Diagnosis of BILI is challenging, often relying on excluding other causes.
• Pharmacogenomic approaches show promise for identifying individuals at higher risk of bleomycin toxicity.

Conclusions:

• Physicians treating HL and GCT patients must be vigilant for BILI.
• Pharmacogenomic studies are essential for developing personalized bleomycin treatment strategies.
• Implementing evidence-based guidelines can enhance the safe use of bleomycin in cancer therapy.